Y-mAbs Therapeutics (YMAB) Misses Q2 EPS by 27c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts YMAB Hot Sheet
Join SI Premium – FREE
Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q2 EPS of ($0.94), $0.27 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $10.8 million versus the consensus estimate of $11.23 million.
For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Latham Group, Inc. (SWIM) Misses Q3 EPS by 5c ; Offers Guidance
- Essential Utilities, Inc. (WTRG) Tops Q3 EPS by 4c
- Triple Flag Precious Metals Corp. (TFPM) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
